Literature DB >> 10203036

HIV-1 infectability of CD4+ lymphocytes with relation to beta-chemokines and the CCR5 coreceptor.

W A Paxton1, S Kang, R Liu, N R Landau, T R Gingeras, L Wu, C R Mackay, R A Koup.   

Abstract

CD4+ lymphocytes exhibit variable permissiveness to the replication of HIV-1. A cohort of sexually-exposed-yet-uninfected individuals were previously shown to have CD4+ lymphocytes refractory for M-tropic viral replication. In particular, two individuals from this population whose CD4+ lymphocytes exhibited complete resistance to M-tropic viral replication were later shown to be homozygous for a 32bp (delta32) deletion in the gene encoding for CCR5. In screening diverse populations, HIV-1 infected individuals heterozygous for the delta32 allele were statistically favored in their disease course to harbor lower viral loads and exhibit slower rates of CD4+ cell loss when compared to control CCR5 wild-type individuals. Further comparative analysis between individuals in the exposed but uninfected cohort who demonstrated intermediate levels of in vitro viral replication and CD4+ lymphocytes isolated from uninfected delta32 heterozygous individuals indicate that reduced levels of in vitro M-tropic replication are a CCR5-related phenomenon: CD4+ lymphocytes from these individuals were more sensitive to the HIV-1 blocking effects of recombinant chemokines, displayed lower CCR5 cell surface expression levels and a proportionate increase in the production of RANTES when compared to CD4+ lymphocytes from control individuals. These results suggest that the CCR5 phenotype is important in determining the replicative capacity of M-tropic HIV-1 in vitro. The implications of these results with relation to HIV-1 transmission and disease progression are discussed.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10203036     DOI: 10.1016/s0165-2478(98)00154-0

Source DB:  PubMed          Journal:  Immunol Lett        ISSN: 0165-2478            Impact factor:   3.685


  8 in total

1.  Concordance of CCR5 genotypes that influence cell-mediated immunity and HIV-1 disease progression rates.

Authors:  Gabriel Catano; Zoya A Chykarenko; Andrea Mangano; J-M Anaya; Weijing He; Alison Smith; Rosa Bologna; Luisa Sen; Robert A Clark; Andrew Lloyd; Ludmila Shostakovich-Koretskaya; Sunil K Ahuja
Journal:  J Infect Dis       Date:  2011-01-15       Impact factor: 5.226

2.  HIV vaccine trial exploits a dual and central role for innate immunity.

Authors:  Deborah Heydenburg Fuller; Laura E Richert-Spuhler; Nichole R Klatt
Journal:  J Virol       Date:  2014-08-13       Impact factor: 5.103

3.  High-Sequence Diversity and Rapid Virus Turnover Contribute to Higher Rates of Coreceptor Switching in Treatment-Experienced Subjects with HIV-1 Viremia.

Authors:  Rebecca Nedellec; Joshua T Herbeck; Peter W Hunt; Steven G Deeks; James I Mullins; Elizabeth D Anton; Jacqueline D Reeves; Donald E Mosier
Journal:  AIDS Res Hum Retroviruses       Date:  2016-10-12       Impact factor: 2.205

4.  Impact of NNRTI compared to PI-based highly active antiretroviral therapy on CCR5 receptor expression, beta-chemokines and IL-16 secretion in HIV-1 infection.

Authors:  C T Burton; G A D Hardy; A K Sullivan; M R Nelson; B Gazzard; F M Gotch; N Imami
Journal:  Clin Exp Immunol       Date:  2002-11       Impact factor: 4.330

5.  Impaired viral entry cannot explain reduced CD4+ T cell susceptibility to HIV type 1 in certain highly exposed individuals.

Authors:  Emily C Speelmon; Devon Livingston-Rosanoff; Anthony L Desbien; Jean Lee; W David Wick; Florian Hladik; M Juliana McElrath
Journal:  AIDS Res Hum Retroviruses       Date:  2008-11       Impact factor: 2.205

6.  RANTES Gene Polymorphisms Associated with HIV-1 Infections in Kenyan Population.

Authors:  Shem P M Mutuiri; Helen L Kutima; Lamech M Mwapagha; James K Munyao; Anthony Kebira Nyamache; Irene Wanjiru; Samoel A Khamadi
Journal:  Dis Markers       Date:  2016-10-16       Impact factor: 3.434

7.  A decline in CCL3-5 chemokine gene expression during primary simian-human immunodeficiency virus infection.

Authors:  Wei Zhao; Bapi Pahar; Juan T Borda; Xavier Alvarez; Karol Sestak
Journal:  PLoS One       Date:  2007-08-08       Impact factor: 3.240

8.  Self-protection of individual CD4+ T cells against R5 HIV-1 infection by the synthesis of anti-viral CCR5 ligands.

Authors:  Yongjun Guan; Sayed Abdelwahab; Roberta Kamin-Lewis; Anthony L DeVico; George K Lewis
Journal:  PLoS One       Date:  2008-10-22       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.